Wave Life Sciences Ltd. Share Price

Equities

WVE

SG9999014716

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 19:28:06 29/04/2024 BST 5-day change 1st Jan Change
4.825 USD +3.54% Intraday chart for Wave Life Sciences Ltd. +0.31% -3.86%
Sales 2024 * 76.38M 6.08B Sales 2025 * 52.83M 4.21B Capitalization 570M 45.37B
Net income 2024 * -119M -9.48B Net income 2025 * -141M -11.23B EV / Sales 2024 * 5.35 x
Net cash position 2024 * 161M 12.84B Net cash position 2025 * 67.89M 5.41B EV / Sales 2025 * 9.5 x
P/E ratio 2024 *
-4.61 x
P/E ratio 2025 *
-4.36 x
Employees 267
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.54%
1 week+0.31%
Current month-21.31%
1 month-23.06%
3 months+8.61%
6 months-10.59%
Current year-3.86%
More quotes
1 week
4.64
Extreme 4.64
5.23
1 month
4.64
Extreme 4.64
6.32
Current year
3.50
Extreme 3.5
7.67
1 year
3.15
Extreme 3.1501
7.67
3 years
1.16
Extreme 1.16
7.67
5 years
1.16
Extreme 1.16
39.98
10 years
1.16
Extreme 1.16
56.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 30/11/13
Director of Finance/CFO 54 30/06/14
Chief Tech/Sci/R&D Officer 63 31/07/14
Members of the board TitleAgeSince
Chairman 56 09/11/16
Director/Board Member 66 03/09/19
Director/Board Member 52 31/01/17
More insiders
Date Price Change Volume
29/04/24 4.85 +4.08% 282 174
26/04/24 4.66 -1.69% 407,036
25/04/24 4.74 -5.39% 397,715
24/04/24 5.01 -1.38% 430,676
23/04/24 5.08 +4.96% 469,439

Delayed Quote Nasdaq, April 29, 2024 at 07:12 pm

More quotes
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.66 USD
Average target price
13 USD
Spread / Average Target
+178.97%
Consensus